Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>In Silico</i> Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment

2 Jun 2016

Abstract excerpt

Triple-negative breast cancer (TNBC) is an incurable disease with poor prognosis. At this moment, therapeutic options are limited to chemotherapy, and no targeted agent has reached the clinical setting. Bromodomain and extraterminal (BET) inhibitors are a new family of compounds that inhibit bromodomain-containing proteins affecting the expression of transcription factors, therefore modifying the expression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27256375
DOI: 10.1158/1535-7163.mct-16-0004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>In Silico</i> Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer TreatmentPMID 27256375Read ↗

BET inhibitors as novel therapeutic agents in breast cancerSemantic proximity Read ↗

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.Semantic proximity Read ↗

BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1Semantic proximity Read ↗

Research on therapeutic clinical trials including immunotherapy in Triple- negative Breast cancer: A bibliometric analysisSemantic proximity Read ↗

Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional MachinerySemantic proximity Read ↗

Targeting BET Bromodomains in CancerSemantic proximity Read ↗

BET proteins regulate homologous recombination‐mediated DNA repair: BRCAness and implications for cancer therapySemantic proximity Read ↗

Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical ProgressionSemantic proximity Read ↗

Epigenetics of Triple-Negative Breast Cancer via Natural CompoundsSemantic proximity Read ↗

Targeting BET bromodomain proteins in cancer: The example of lymphomasSemantic proximity Read ↗

Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasmsSemantic proximity Read ↗

Bromodomain Drug Discovery – the Past, the Present, and the FutureSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.